Developing a test to predict early treatment failure in follicular lymphoma
Official title: Assay Development and Prognostic Model for Predicting Early Clinical Failure in Follicular Lymphoma
Funded at University of Arizona · NIH-10947165 · Data updated 2026-11-12
This study is looking to help doctors better predict which patients with follicular lymphoma might not respond well to standard treatment, using a special test on tissue samples to find important genetic clues, so they can create more personalized treatment plans for you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Arizona NIH-funded |
| Lab location | 1 site (Tucson, United States) |
| Project start | September 19, 2024 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $206,968 |
| NIH project number | 1UH2CA292129-01 |
| Project ID | NIH-10947165 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with symptomatic or high-tumor burden follicular lymphoma who are starting immunochemotherapy.
✕Less likely to help
Patients with asymptomatic or low-tumor burden follicular lymphoma who are being managed by observation may not benefit from this research.
What this research studies
This research focuses on improving the ability to predict early clinical failure in patients with follicular lymphoma, a common type of non-Hodgkin lymphoma. By refining a gene expression assay that analyzes tissue samples, the study aims to identify patients who are at risk of not responding well to standard immunochemotherapy treatment. The approach utilizes advanced technology to analyze genetic markers in biopsies, which could help tailor treatment plans more effectively. Patients will be monitored to see if they achieve a specific event-free survival status after treatment, which is crucial for determining their long-term outcomes.
Why it matters
Potential benefit: If successful, this research could lead to more accurate predictions of treatment outcomes, allowing for personalized treatment strategies that improve patient survival rates.
How similar studies have gone: Previous research has shown promise in using gene expression signatures to predict treatment outcomes in various cancers, suggesting that this approach may be effective for follicular lymphoma as well.
Where this research is happening
-
University of Arizona
Tucson, United States Active
Researchers
- Principal investigator: Rimsza, Lisa — University of Arizona
- Study coordinator: Rimsza, Lisa
Related research
Other NIH-funded projects on the same topics.
-
Preventing follicular lymphoma progression with precision therapy
This grant tests a targeted approach to stop follicular lymphoma from getting worse or turning into a more aggressive cancer.
-
Follicular Lymphoma: Better Diagnosis and Personalized Risk in B-Cell Lymphomas
This NIH grant aims to improve how doctors diagnose and predict outcomes for people with follicular lymphoma by finding reliable biomarkers to guide treatment decisions.
-
IRF4's role in shaping the tumor environment in follicular lymphoma
This grant aims to understand how a molecule called IRF4 changes the tumor surroundings in follicular lymphoma to identify potential new ways to help patients.
-
Gene test to predict early treatment failure in follicular lymphoma
A lab test that reads genes in lymphoma biopsy tissue to spot people with follicular lymphoma who are likely to have their disease return within two years after standard immunochemotherapy.
-
How mutant STAT6 affects follicular lymphoma
This project looks at how a gene change called STAT6 affects follicular lymphoma to help find better treatments for people with this cancer.
-
Preventing the progression of follicular lymphoma with targeted therapy
This study is looking at how slow-growing follicular lymphomas can change into more aggressive forms, and it's working to find personalized treatments that target the specific factors that help these tumors survive, so we can help patients live better and longer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.